8,18 Motor and proprioceptive deficits predominate over autonomic symptoms and pain in CIDP. 1 This is attributed to greater susceptibility of motor and proprioceptive nerve fibers to ...

Chronic inflammatory demyelinating polyneuropathy is an immune-mediated neuropathy that affects the peripheral motor and sensory nerves. The symptoms are of a slowly progressive numbness and tingling ...

The company said that Vyvgart (efgartigimod alfa) is the first novel mechanism of action for CIDP treatment in more than 30 years.

Amsterdam, the Netherlands Tuesday, April 29, 2025, 10:00 Hrs [IST] ...

Chronic inflammatory demyelinating polyradiculoneuropathy (CIDP) is a progressive or relapsing neuropathy likely caused by an autoimmune attack on the peripheral nerves. A number of treatment ...

Please note that the MG-ADL score is an 8-item scale that measures the impact of MG symptoms on daily activities ... study is evaluating batoclimab in CIDP patients whose disease had worsened ...

The US FDA has said it plans to deliver a decision in June on the use of Argenx’ Vyvgart Hytrulo in chronic inflammatory demyelinating polyneuropathy (CIDP), as the company tries to turn around ...

Netherlands biotech Argenx has a second FDA approval for its FcRn inhibitor Vyvgart Hytrulo, adding a new indication in chronic inflammatory demyelinating polyneuropathy (CIDP) for a drug that it ...

Today's results show that deeper IgG reduction leads to deeper responses in MG and CIDP. Beyond the results in MG and CIDP, we believe that our core thesis - that deeper IgG reduction, at the levels ...